Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
Open Access
- 18 February 2021
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 23 (6), 1012-1022
- https://doi.org/10.1002/ejhf.2131
Abstract
Aims Use of sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) in real‐world heart failure (HF) is poorly characterised. In contemporary patients with HF and type 2 diabetes (T2DM) we assessed overtime SGLT2i use, clinical characteristics and outcomes associated with SGLT2i use. Methods and Results T2DM patients enrolled in the Swedish HF Registry between 2016‐2018 were considered. We performed multivariable logistic regression models to assess the independent predictors of SGLT2i use and Cox regression models in a 1:3 propensity score‐matched cohort and relevant sub‐groups to investigate the association between SGLT2i use and outcomes. Of 6805 eligible HF patients with T2DM, 376 (5.5%) received SGLT2i, whose use increased over time with 12% of patients on treatment at the end of 2018. Independent predictors of SGLT2i use were younger age, HF‐specialty care, ischemic heart disease, preserved kidney function, and absent anaemia. Over a median follow‐up of 256 days, SGLT2i use was associated with a 30% lower risk of CV death/first HF hospitalisation [hazard ratio (HR): 0.70 (95% confidence interval: 0.52‐0.95)], which was consistent regardless of ejection fraction (EF), background metformin treatment and kidney function. SGLT2i use was also associated with lower risk of all‐cause and CV death, HF and CV hospitalisation, and of CV death/myocardial infarction/stroke. Conclusion In a contemporary HF cohort with T2DM, SGLT2i use increased over time, was more common with specialist care, younger age, ischemic heart disease, and preserved renal function, and was associated with lower mortality and morbidity.This publication has 32 references indexed in Scilit:
- Association between renin–angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort studyEuropean Heart Journal, 2018
- The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failureUpsala Journal of Medical Sciences, 2018
- Canagliflozin and Heart Failure in Type 2 Diabetes MellitusCirculation, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 2017
- Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort studyEuropean Journal of Heart Failure, 2017
- Global Public Health Burden of Heart FailureCardiac Failure Review, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Association between diabetes mellitus and post‐discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trialEuropean Journal of Heart Failure, 2013
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEuropean Heart Journal, 2008
- Cardiovascular Diabetology, 2003